J Cancer 2018; 9(7):1259-1266. doi:10.7150/jca.23992
Reassessing the Potential of Myb-targeted Anti-cancer Therapy
1. Department of Hematology, the Second Xiangya Hospital, Central South University, Changsha, Hunan Province, P.R. China
2. School of Life Science, Changchun Normal University, Changchun, Jilin Province, P.R. China
Liu X, Xu Y, Han L, Yi Y. Reassessing the Potential of Myb-targeted Anti-cancer Therapy. J Cancer 2018; 9(7):1259-1266. doi:10.7150/jca.23992. Available from http://www.jcancer.org/v09p1259.htm
Transcription factor MYB is essential for the tumorigenesis of multiple cancers, especially leukemia, breast cancer, colon cancer, adenoid cystic carcinoma and brain cancer. Thus, MYB has been regarded as an attractive target for tumor therapy. However, pioneer studies of antisense oligodeoxynucleotides against MYB, which were launched three decades ago in leukemia therapy, were discontinued because of their unsatisfactory clinical outcomes. In recent years, the roles of MYB in tumor transformation have become increasingly clear. Moreover, the regulatory mechanisms of MYB, such as the vital effects of MYB co-regulators on MYB activity and of transcriptional elongation on MYB expression, have been unveiled. These observations have underpinned novel approaches in inhibiting MYB. This review discusses the structure, function and regulation of MYB, focusing on recent insights into MYB-associated oncogenesis and how MYB-targeted therapeutics can be explored. Additionally, the main MYB-targeted therapies, including novel genetic therapy, RNA interference, microRNAs and low-molecular-weight compounds, which are especially promising inhibitors that target MYB co-regulators and transcriptional elongation, are described, and their prospects are assessed.
Keywords: MYB, MYB inhibitor, therapeutic strategy, targeted therapy, anti-cancer therapy